Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims

Amgen Inc.'s latest bid to knock out patents a Kansas-based company alleges the blockbuster osteoporosis drug Evenity infringes leans on case law rooted in Amgen’s own recent Supreme Court enablement loss and doesn’t undermine the patents, OssiFi-Mab LLC said.

OssiFi-Mab made the argument in a response filed Monday to Amgen’s second notice of supplemental authority supporting its motions for summary judgment in the US District Court for the District of Massachusetts.

The April 2023 lawsuit seeks royalties for a treatment that had US sales of $1.1 billion in 2024, nearly 3.4% of Amgen’s overall revenue, according to data compiled by ...